Another Denosumab Deal For mAbxience In MEA

MS Pharma Is Set To Register And Market The Prolia/Xgeva Biosimilar In MEA Markets

 
• By David Wallace
  
View of Earth highlighting middle east and Africa
MS Pharma will market mAbxience’s denosumab in MEA territories • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business